Biogen IDEC Inc.

BIIB-Q

NASDAQ:BIIB

280.29
13.62 (5.11%)
Biogen, Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, ...
More at Wikipedia

Analysis and Opinions about BIIB-Q

Signal
Opinion
Expert
TOP PICK
TOP PICK
November 26, 2020

Stockchase Research Editor: Michael O'Reilly BIIB has been on a roller-coaster. When the FDA announced a priority review of a new Alzheimer's drug, it stock soared to $360. When the review failed to approve the drug in the first go-round, the stock plunged to under $250 -- so it goes with drug manufacturers. Its MS drugs continue to do well and it is working on treatments for Parkinson's disease as well. Trading at 8x earnings, it is cheap compared to peers at 30x. We would buy this with a $180 stop-loss looking to achieve $305 -- 26% upside. Yield 0%. (Analysts’ price target is $305.90)

Show full opinionHide full opinion
Biogen IDEC Inc. (BIIB-Q)
November 26, 2020

Stockchase Research Editor: Michael O'Reilly BIIB has been on a roller-coaster. When the FDA announced a priority review of a new Alzheimer's drug, it stock soared to $360. When the review failed to approve the drug in the first go-round, the stock plunged to under $250 -- so it goes with drug manufacturers. Its MS drugs continue to do well and it is working on treatments for Parkinson's disease as well. Trading at 8x earnings, it is cheap compared to peers at 30x. We would buy this with a $180 stop-loss looking to achieve $305 -- 26% upside. Yield 0%. (Analysts’ price target is $305.90)

BUY
BUY
November 4, 2020
The FDA found Biogen's Alzheimer's drug effective and exploded 44% today amid the post-election rally. Overall, healthcare stocks have more room to run. You need to own some healthcare in a portfolio.
Show full opinionHide full opinion
Biogen IDEC Inc. (BIIB-Q)
November 4, 2020
The FDA found Biogen's Alzheimer's drug effective and exploded 44% today amid the post-election rally. Overall, healthcare stocks have more room to run. You need to own some healthcare in a portfolio.
DON'T BUY
DON'T BUY
October 20, 2020

https://www.pmlive.com/pharma_news/fda_sets_november_date_for_expert_panel_review_of_biogens_aducanumab_1351831 Until February 2020, Biogen's FDA results of an Alzheimer drug was the healthcare event of the year (then Covid hit). Novartis and other players are starting to compete here, though. He owned Biogen some years ago. He was on a panel which was split over whether Biogen would get FDA approval on Nov. 6. Regardless, this is a high-risk play; this could pop 35-50% up or down. The risk/return is too much for him. The drug has a checkered past and so far there is no effective Alzheimer's drug, but if it works it will be huge for the company and society.

Show full opinionHide full opinion
Biogen IDEC Inc. (BIIB-Q)
October 20, 2020

https://www.pmlive.com/pharma_news/fda_sets_november_date_for_expert_panel_review_of_biogens_aducanumab_1351831 Until February 2020, Biogen's FDA results of an Alzheimer drug was the healthcare event of the year (then Covid hit). Novartis and other players are starting to compete here, though. He owned Biogen some years ago. He was on a panel which was split over whether Biogen would get FDA approval on Nov. 6. Regardless, this is a high-risk play; this could pop 35-50% up or down. The risk/return is too much for him. The drug has a checkered past and so far there is no effective Alzheimer's drug, but if it works it will be huge for the company and society.

BUY WEAKNESS
BUY WEAKNESS
October 6, 2020
He bought it two months ago. They have a diabetes drug candidate, the only company.. They have a history of above-average returns, which ticks that box. Buy at $250-270 If the drug is approved, he predicts the stock to hit $350-400.
Show full opinionHide full opinion
He bought it two months ago. They have a diabetes drug candidate, the only company.. They have a history of above-average returns, which ticks that box. Buy at $250-270 If the drug is approved, he predicts the stock to hit $350-400.
DON'T BUY
DON'T BUY
September 24, 2019
The sector has done poorly, and the summer is seasonality. A lot of this has to do with the US election campaign with candidates offering cheap/free healthcare. BIIB fell below support at $250. He is avoiding the entire space.
Show full opinionHide full opinion
Biogen IDEC Inc. (BIIB-Q)
September 24, 2019
The sector has done poorly, and the summer is seasonality. A lot of this has to do with the US election campaign with candidates offering cheap/free healthcare. BIIB fell below support at $250. He is avoiding the entire space.
SELL
SELL
May 15, 2019
He doesn't like their chart. Sell if it closes below $220. Institutions are selling it, and it's selling on weak volume. Had a big breakdown in latter 2018. Look elsewhere.
Show full opinionHide full opinion
He doesn't like their chart. Sell if it closes below $220. Institutions are selling it, and it's selling on weak volume. Had a big breakdown in latter 2018. Look elsewhere.
COMMENT
COMMENT
May 3, 2019
Demonstrates how binary risk can happen in individual securities. Big driver recently has been failure in an Alzheimer's study. Had to shut the study down, which caught the market by surprise. Likes it, though risk in this stock is high, with a relatively high rate of return. For all large cap biotech, make sure you have at least a couple of positions.
Show full opinionHide full opinion
Demonstrates how binary risk can happen in individual securities. Big driver recently has been failure in an Alzheimer's study. Had to shut the study down, which caught the market by surprise. Likes it, though risk in this stock is high, with a relatively high rate of return. For all large cap biotech, make sure you have at least a couple of positions.
DON'T BUY
DON'T BUY
March 22, 2019
Indicators are quite oversold. Lots of action around $219 from 2013. He very rarely plays individual biotech names for this very reason. It's high beta, so it's more volatile than the market. He prefers to buy the biotech ETF. If it breaks $198, it will probably go to $150.
Show full opinionHide full opinion
Indicators are quite oversold. Lots of action around $219 from 2013. He very rarely plays individual biotech names for this very reason. It's high beta, so it's more volatile than the market. He prefers to buy the biotech ETF. If it breaks $198, it will probably go to $150.
TOP PICK
TOP PICK
July 17, 2018

A large bio-pharma. They enjoyed a recent jump in the stock price had to do with seeing promising results from a phase 2 trial drug treating Alzheimer's. If this drug ultimately passes, it would be an multi-billion-dollar opportunity. Free cash flow is a high 7%. They'll likely make an acqusition with all this cash to deepend their portfolio. (Analysts' price target: $365.00)

Show full opinionHide full opinion

A large bio-pharma. They enjoyed a recent jump in the stock price had to do with seeing promising results from a phase 2 trial drug treating Alzheimer's. If this drug ultimately passes, it would be an multi-billion-dollar opportunity. Free cash flow is a high 7%. They'll likely make an acqusition with all this cash to deepend their portfolio. (Analysts' price target: $365.00)

DON'T BUY
DON'T BUY
May 3, 2018

He Prefers VRTX-Q. You need to invest in the most innovative companies in this sector.

Show full opinionHide full opinion

He Prefers VRTX-Q. You need to invest in the most innovative companies in this sector.

PAST TOP PICK
PAST TOP PICK
March 14, 2018

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

Show full opinionHide full opinion

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

BUY
BUY
March 14, 2018

He loves when good companies pullback in price. He would be tempted to buy here and more if it fell to $240. His model price is $402.

Show full opinionHide full opinion

He loves when good companies pullback in price. He would be tempted to buy here and more if it fell to $240. His model price is $402.

PARTIAL SELL
PARTIAL SELL
October 2, 2017

Seasonal strength is from May until the end of September. It is an opportunity to take some money off the table.

Show full opinionHide full opinion

Seasonal strength is from May until the end of September. It is an opportunity to take some money off the table.

DON'T BUY
DON'T BUY
September 14, 2017

It has a large franchise in MS which comprises 75% of their business. He is seeing potential threat to this franchise from two companies. Their Alzheimer’ drug comes to trial in 2019 and has high risk.

Show full opinionHide full opinion
Biogen IDEC Inc. (BIIB-Q)
September 14, 2017

It has a large franchise in MS which comprises 75% of their business. He is seeing potential threat to this franchise from two companies. Their Alzheimer’ drug comes to trial in 2019 and has high risk.

COMMENT
COMMENT
June 28, 2017

US healthcare for the long-term? As opposed to picking just one stock in a sector, your best bet probably is an ETF. If you are looking for an individual stock, one that he holds is Biogen. It is quite cheap relative to its ability to grow earnings.

Show full opinionHide full opinion

US healthcare for the long-term? As opposed to picking just one stock in a sector, your best bet probably is an ETF. If you are looking for an individual stock, one that he holds is Biogen. It is quite cheap relative to its ability to grow earnings.

Showing 1 to 15 of 31 entries

Biogen IDEC Inc.(BIIB-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Biogen IDEC Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Biogen IDEC Inc.(BIIB-Q) Frequently Asked Questions

What is Biogen IDEC Inc. stock symbol?

Biogen IDEC Inc. is a American stock, trading under the symbol BIIB-Q on the NASDAQ (BIIB). It is usually referred to as NASDAQ:BIIB or BIIB-Q

Is Biogen IDEC Inc. a buy or a sell?

In the last year, 3 stock analysts published opinions about BIIB-Q. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Biogen IDEC Inc..

Is Biogen IDEC Inc. a good investment or a top pick?

Biogen IDEC Inc. was recommended as a Top Pick by Stockchase Research on 2020-11-26. Read the latest stock experts ratings for Biogen IDEC Inc..

Why is Biogen IDEC Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Biogen IDEC Inc. worth watching?

3 stock analysts on Stockchase covered Biogen IDEC Inc. In the last year. It is a trending stock that is worth watching.

What is Biogen IDEC Inc. stock price?

On 2021-01-14, Biogen IDEC Inc. (BIIB-Q) stock closed at a price of $280.29.